New

AI v2.0 Beta Launched. Experience the future of pharmaceutical care.

Try Now
Drug info language
Switches all medical info on this page (labels, indications, leaflet) without changing the rest of the interface.
CNASHighly Regulated (List I)

BETAFERON

250µG/ML (8MUI/ML) DE SOL. RECONSTITUEE/Powder + Solvent for SC Injectable Sol./INTERFERON BETA-1B RECOMBINANT
BAYER
ManufacturerVerified lab

BAYER

Public retail price
72277.75DZD
Reference price (TR): 76141.95 DZD

Identification

Active ingredient (INN)
INTERFERON BETA-1B RECOMBINANT
Internal code
15 G 096
Country of Origin
Germany
Pharmaceutical form
Powder + Solvent for SC Injectable Sol.
Prescription List
Highly Regulated (List I)
Packaging
b/15presentations unitaires contenant chacune 1flacon de pdre.+1sering.preremplie de 1.2ml de solv.+2tampons imbibes d'alcool+1adapteur pour flacon avec aiguille
BETAFERON
Clinical View
CNAS
Highly Regulated (List I)

DAWA Clinical Workbench v2.0

Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.

Description

Human interferon beta (165 residues), cysteine is substituted with serine.

Indications

Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis.

It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.

Pharmacodynamics

Interferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens.

This enhances the activation of

CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing.

I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R.

Mechanism of Action

Interferon alpha/beta receptor 1 Agonist Interferon alpha/beta receptor 2 Agonist.

Adverse Effects

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

Warnings

Stop use and ask doctor if symptoms persist more than 5 days or worsen.

If pregnant or breast-feeding ask a health professional before use.

Keep out of reach of children.

Dosage & Administration

Take 15 minutes before meals Adults and children 12 years and older 5 pellets 3 times per day Children between 12 years and 6 years of age 3 pellets 3 times per day Children under 6 years 1 pellet 3 times per day to be disoolved into a little water.

Alternatives